Zim Laboratories Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company is focused on CapEx investments, with a Rs. 25 Crore CapEx planned for the next quarter and ongoing investments based on regulatory and strategic requirements. - CapEx decisions beyond the ongoing investments will be made post-audit, indicating no immediate new fundraising plans. - The discussion also highlights internal funding of expansion and R&D activities without reference to raising external capital. - Overall, the company appears to be managing funded growth through operational cash flows and planned CapEx, with no indication of imminent debt or equity fundraising.

- Anwar Daud and Shyam Patro mentioned ongoing and future CapEx investments aligned with regulatory needs and strategic expansion. - Next quarter CapEx investment expected around Rs. 25 Crore. - CapEx is focused on debottlenecking, capacity expansion, and regulatory compliance, including preparations for ANVISA inspections in South American markets like Brazil and Mexico. - There is a plan to double overall capacity in the next two years, with a 25% to 40% capacity enhancement expected in the coming couple of years. - Additional CapEx decisions will be made post-audit based on future requirements. - CapEx supports the rollout and scaling of new innovative products (NIPs) and Oral Thin Film (OTF) technologies. - The investment aims to position ZIM for growth in regulated markets (Europe, Brazil, Mexico, Southeast Asia) and support regulatory filings and approvals. - CapEx spending aligns with strategy to improve R&D and market compliance.

- FY'25 sales expected to reflect contributions from regulated markets filings and supplies, signaling growth potential. - NIP (New Innovative Products) portfolio anticipated to expand from 4 to 7-8 by FY'25, indicating pipeline growth. - Margins expected to improve to 15%-17% EBITDA if conditions remain favorable. - Regulatory filings in Europe and other markets forecast 1.5 to 2 years for approvals, with rollout starting FY'25 and scaling over time. - NIP and Oral Thin Film (OTF) products could contribute up to 30%-40% of overall revenues in the near term. - Capacity enhancements planned at 25%-40% over the next two years, potentially doubling overall capacity, supporting volume growth. - Despite challenges (currency issues, Red Sea crisis), easing conditions and expanding geographic footprint are expected to stabilize and improve revenue streams. - India business and Nutraceutical segments show consistent margin improvements and growth potential.

- EBITDA margin is expected to improve from current 12%-13% to around 15%-17% if conditions are favorable (Page 20). - NIP and ODS products are projected to contribute significantly, potentially reaching 30%-40% of overall business in the next 2-3 years (Pages 13, 16). - European and regulated market rollout of NIP products expected from FY'25, likely driving strong revenue growth (Pages 16, 21). - Volume growth in FY'25 and FY'26 is anticipated as new product filings mature and approvals come through (Pages 12, 16). - Capacity expansion aims to double output in the next two years, supporting revenue growth (Page 7, 8). - Currency issues impacting short-term revenue but expected to ease, supporting recovery in earnings (Page 19). - Order pipeline and out-licensing fees growing, indicating rising commercial traction ahead (Page 8). Overall, earnings growth is expected driven by NIP product traction, capacity expansion, and entry into regulated markets with improved margins.

- There is a robust order list for Nutraceutical products, with several orders in hand. - Some supply is pending due to currency issues in certain markets, as supplies are against advance payments. - A single Nutra order from last year, worth about Rs. 20 crores, was not repeated due to currency constraints. - The business saw a revenue loss of approximately Rs. 20 crores last year linked to currency issues. - Supply has started for filings done in regulated markets, with agreements made and orders flowing in. - NIP and ODS product orders have started contributing to business, with strong growth expected in FY25. - More order inflows from European and regulated markets are anticipated as MA approvals come through in 1.5 to 2 years post-filing.